COMMUNIQUÉS West-GlobeNewswire

-
TrainHealth Announces FDA Clearance of TrainFES Advanced, Improving Results in Neurological Rehabilitation
18/03/2025 -
Breakthrough T1D Canada calls on the Quebec government to remove age restrictions for insulin pumps
18/03/2025 -
Percée DT1 Canada demande au gouvernement du Québec d'éliminer les restrictions d'âge pour les pompes à insuline
18/03/2025 -
ZHITTYA GENESIS MEDICINE ANNOUNCES: DR. JACK JACOBS, PRESIDENT, TO RECEIVE NEVADABIO HONOR FOR PARKINSON’S DISEASE BREAKTHROUGH
18/03/2025 -
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk
18/03/2025 -
Iantrek Announces Positive 2-Year Results Demonstrating Efficacy and Safety of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Glaucoma Patients
18/03/2025 -
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
18/03/2025 -
VITAS® Healthcare Is First Hospice Organization to Earn American Heart Association Heart Failure Certification Across All 15 States and DC
18/03/2025 -
Former Special Operations Intelligence Officer and Consulting Leader, Anthony Chapman, joins Board of Directors of Healthcare Integrated Technologies Inc.
18/03/2025 -
HealthEquity Assist™: A new suite of integrated benefit solutions that drive deeper engagement, deliver cost savings, and increase transparency for employee benefits
18/03/2025 -
GRI Bio Participates in a Virtual Investor CEO Connect Segment
18/03/2025 -
Celebrating a Decade of Care: Aeroflow Urology Marks 10 Years of Supporting Those Afflicted by Incontinence Across the U.S.A.
18/03/2025 -
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today’s Marketplace
18/03/2025 -
Leading Academic and Manufacturing Organizations Join Ori Biotech’s Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies
18/03/2025 -
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
18/03/2025 -
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
18/03/2025 -
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
18/03/2025 -
Outset Medical Announces One-for-Fifteen Reverse Stock Split
18/03/2025 -
Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025
18/03/2025
Pages